A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Exclusion criteria

• ✕. Prior cytotoxic chemotherapy or radiotherapy for this lymphoma other than palliative radiation for medical emergencies (like cord compression) or the following chemotherapy:
• ✕. Patients who are receiving any other investigational agents.
• ✕. Participants must not have had previous anthracycline treatment within the last two years, except for liposomal doxorubicin. Any prior exposure to liposomal doxorubicin is allowed as long as the LVEF is ≥45%. It is at the discretion of the investigator if prior exposure to doxorubicin is acceptable.
• ✕. Participants who have previously received daratumumab for another indication.
• ✕. Participants must not be on cobicistat, indinavir, or ritonavir, or agents that are strong CYP3A4 inhibitors. If on a strong CYP3A4 inhibitor regimen prior to study enrollment, participants must be switched to alternative drugs at least one week prior to administration of study therapy.
• ✕. Participants with peripheral neuropathy grade ≥ 3 or neuropathic pain grade ≥ 2.
• ✕. Expected survival \< 2 months.
• ✕. Participants with known brain metastases from solid tumors will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.